Therapeutic peptides: Historical perspectives, current development trends, and future directions

Banting, 1922, Pancreatic extracts in the treatment of diabetes mellitus, Can Med Assoc J, 12, 141

Elkinton, 1949, Effects of pituitary adrenocorticotropic hormone (ACTH) therapy, J Am Med Assoc, 141, 1273, 10.1001/jama.1949.02910180001001

Di, 2014, Strategic approaches to optimizing peptide ADME properties, AAPS J, 17, 134, 10.1208/s12248-014-9687-3

Hollenstein, 2014, Insights into the structure of class B GPCRs, Trends Pharmacol Sci, 35, 12, 10.1016/j.tips.2013.11.001

Agoulnik, 2017, Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1, Br J Pharmacol, 174, 977, 10.1111/bph.13656

Mishra, 2016, Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists, Sci Rep, 6, 30155, 10.1038/srep30155

Drugs@FDA. Accessed April 23, 2017.

Hollenberg, 1976, Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man, J Clin Invest, 57, 39, 10.1172/JCI108266

Mullard, 2014, Once-yearly device takes on daily and weekly diabetes drugs, Nat Biotechnol, 32, 1178, 10.1038/nbt1214-1178

Camacho, 2016, American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2016, Endocr Pract, 22, 1, 10.4158/EP161435.GL

Stupp, 2014, Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol, 15, 1100, 10.1016/S1470-2045(14)70379-1

Chang, 2013, Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy, Proc Natl Acad Sci USA, 110, E3445, 10.1073/pnas.1303002110

Meerovitch, 2013, Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye, Clin Ophthalmol, 7, 1275, 10.2147/OPTH.S44688

Birk, 2013, The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin, J Am Soc Nephrol, 24, 1250, 10.1681/ASN.2012121216

Reichert J, Pechon P, Tartar A, Dunn MK. Development trends for peptide therapeutics: A comprehensive quantitative analysis of peptide therapeutics in clinical development. 2010.

Saladin, 2009, Current trends in the clinical development of peptide therapeutics, IDrugs., 12, 779

Bray, 2003, Large-scale manufacture of peptide therapeutics by chemical synthesis, Nat Rev Drug Discov, 2, 587, 10.1038/nrd1133

Thayer, 2011, Making Peptides at Large Scale, Vol. 89, 21

Behrendt, 2015, Offer JCPSC. Advances in Fmoc solid-phase peptide synthesis, J Pept Sci, 22, 4, 10.1002/psc.2836

Hannon, 2002, Drug design at peptide receptors: somatostatin receptor ligands, J Mol Neurosci, 18, 15, 10.1385/JMN:18:1-2:15

Fricker, 1991, Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence derivatization, Gastroenterology, 100, 1544, 10.1016/0016-5085(91)90651-Z

Bussel, 2006, AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP, N Engl J Med, 355, 1672, 10.1056/NEJMoa054626

Peng, 2015, Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models, Mol Cancer Ther, 14, 480, 10.1158/1535-7163.MCT-14-0850

Madsbad, 2016, Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists, Diabetes Obes Metab, 18, 317, 10.1111/dom.12596

Clemmensen, 2017, Gut-brain cross-talk in metabolic control, Cell, 168, 758, 10.1016/j.cell.2017.01.025

Saveaunu A, Datta R, Zhang S, et al. Novel Somatostatin-Dopamine Chimeric Compound Demonstrates Superior Efficacy in Suppressing Growth Hormone Secretion from Human Acromegalic Tumors Partially Responsive to Current Somatostatin and Dopamine Therapies. Paper presented at: ENDO 2016; Boston, MA.

Finan, 2013, Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans, Sci Transl Med, 5, 10.1126/scitranslmed.3007218

Konkar A, Suckow A, Hummer T, et al. MEDI4166: a PCSK9 Ab-GLP-1 fusion molecule that elicits robust antidiabetic and antihyperlipidaemic effects in rodents and non-human primates. Paper presented at: European Association for the Study of Diabetes 2016; Munich, Germany.

Thomas DW, Burns J, Audette J, Carroll A, Dow-Hygelund C, Hay M. Clinical development success rates 2006–2015. 2016. <https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf>.

DiMasi, 2013, Clinical approval success rates for investigational cancer drugs, Clin Pharmacol Ther, 94, 329, 10.1038/clpt.2013.117

CMR International. 2015 CMR International Pharmaceutical R&D Factbook. 2015.

Abbara, 2015, Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy, J Clin Endocrinol Metab, 100, 3322, 10.1210/jc.2015-2332

Kühnen, 2016, Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist, N Engl J Med, 375, 240, 10.1056/NEJMoa1512693

McKeown, 2014, The design and implementation of a generic lipopeptide scanning platform to enable the identification of 'locally acting' agonists for the apelin receptor, Bioorg Med Chem Lett, 24, 4871, 10.1016/j.bmcl.2014.08.045

Jia, 2012, Cardiovascular effects of a PEGylated apelin, Peptides, 38, 181, 10.1016/j.peptides.2012.09.003

Schönauer, 2016, Adrenomedullin 2.0: adjusting key levers for metabolic stability, J Med Chem, 59, 5695, 10.1021/acs.jmedchem.6b00126

Ohtaki T, Masuda Y, Kuman S, Inooka H, Inventors; Takeda Pharmaceutical Company Limited, assignee. Neuromedin U derivative. US patent 9,175,037; 2015.

Masuda, 2017, PEGylated neuromedin U-8 shows long-lasting anorectic activity and anti-obesity effect in mice by peripheral administration, Peptides, 10.1016/j.peptides.2017.04.001

A Study of CLR325 in Chronic Stable Heart Failure Patients (NCT02696967). Clinicaltrials.gov. National Institutes of Health. Accessed June 12, 2017.

Ling, 2015, A new antibiotic kills pathogens without detectable resistance, Nature, 517, 455, 10.1038/nature14098

Motley, 2017, Opportunistic sampling of roadkill as an entry point to accessing natural products assembled by bacteria associated with non-anthropoidal mammalian microbiomes, J Nat Prod, 80, 598, 10.1021/acs.jnatprod.6b00772

Lavergne, 2015, Optimized deep-targeted proteotranscriptomic profiling reveals unexplored Conus toxin diversity and novel cysteine frameworks, Proc Natl Acad Sci USA, 112, E3782, 10.1073/pnas.1501334112

Romere, 2016, Asprosin, a fasting-induced glucogenic protein hormone, Cell, 165, 566, 10.1016/j.cell.2016.02.063

Walther, 2000, A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR, Mol Cell, 5, 831, 10.1016/S1097-2765(00)80323-8

Brayden, 2016, Oral delivery of peptides: opportunities and issues for translation, Adv Drug Deliv Rev, 106, 193, 10.1016/j.addr.2016.10.005

Melmed, 2015, Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial, J Clin Endocrinol Metab, 100, 1699, 10.1210/jc.2014-4113

Lalatsa, 2014, Strategies to deliver peptide drugs to the brain, Mol Pharm, 11, 1081, 10.1021/mp400680d

Hill, 2012, Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial, Lancet Neurol, 11, 942, 10.1016/S1474-4422(12)70225-9